Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Davis

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|July 7, 2021
Consensus-Driven Priorities for Firearm Injury Education Among Medical ProfessionalsKatherine Hoops, Jahan Fahimi, Lina Khoeur, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|July 7, 2021
Consensus-Driven Priorities for Firearm Injury Education Among Medical ProfessionalsKatherine Hoops, Jahan Fahimi, Lina Khoeur, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Pageof 9